5:43 PM
 | 
Mar 25, 2013
 |  BC Extra  |  Company News

Japan approves metreleptin along with others

Japan's Ministry of Health, Labor and Welfare (MHLW) approved a number of drugs on Monday, including metreleptin from Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507) to treat lipodystrophy. Shionogi has Japanese rights to the product from Amylin Pharmaceuticals Inc., which Bristol-Myers Squibb Co. (NYSE:BMY) acquired last year. A BLA is under FDA review to treat diabetes and/or hypertriglyceridemia in patients with rare forms of lipodystrophy. Japan also approved an NDA from Kyowa Hakko Kirin...

Read the full 362 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >